Chinese instructions for lpilimumab

1. Drug name:

Ipilimumab (lpilimumab)

2. Indications:

Ipilimumab is used to treat:

1.Treatment of malignant melanoma (melanoma), especially advanced or metastatic melanoma.

2.Treatment of advanced colorectal cancer.

3. Mechanism of action:

Ipilimumab is an immune checkpoint inhibitor. Its main mechanism of action is to enhance the activity of the immune system by inhibiting CTLA-4 (cytotoxic Tlymphocyte antigen 4). CTLA-4 is a protein that negatively regulates immune response. It can inhibit the activity of T lymphocytes and reduce the immune system’s attack on cancer cells. Ipilimumab works to relieve the suppression of the immune system by CTLA-4, making it easier for T lymphocytes to attack cancer cells.

4. Pharmacology:

Ipilimumab is administered through intravenous injection. After entering the blood circulation, it binds to the CTLA-4 protein and prevents the binding of CTLA-4 to its ligands (B7-1 and B7-2). This can enhance the activity of TT lymphocytes and improve their ability to recognize and attack cancer cells.

5. Dosage and usage:

The dosage and administration of ipilimumab will vary based on the patient's specific condition, cancer type, and treatment plan. The following are general usage and dosage guidelines:

1.Ipilimumab is usually administered intravenously at a dose of 3 mg/kg (mg/kg) per treatment course. Dosage is calculated based on patient weight.

2.The treatment cycle and total number of courses will be determined based on the patient's condition and the doctor's recommendations.

3.Doctors and professional medical teams will ensure monitoring and management of the treatment process.

6. Side effects:

Ipilimumab may cause a series of adverse reactions, including but not limited to:

1.Immune-related skin inflammation, such as rash, itching, and dry skin.

2.Immune-related gastrointestinal problems such as diarrhea, nausea, vomiting, and abdominal pain.

3.Immune-related thyroid disease, such as hyperthyroidism or hypothyroidism.

4.Immune-related pneumonia, which may cause difficulty breathing and coughing.

5.Immune-related liver function abnormalities, such as jaundice and elevated liver enzymes.

6.Immune-related neurological problems, such as neuritis and paresthesia.

7.Immune-related endocrine problems, such as adrenal gland dysfunction.

8.Patients should pay close attention to any adverse reactions during treatment and contact their doctor in time. These adverse reactions usually require treatment and management by a physician.

7. Warnings and precautions:

Be aware of the following warnings and precautions when using ipilimumab:

1.Immune-related adverse reactions: Ipilimumab may cause immune-related adverse reactions, including severe immune skin inflammation, gastrointestinal problems, thyroid disease, etc. Physicians need to monitor patients' symptoms closely and take appropriate steps to manage these adverse effects.

2.Immune-related pneumonia: Ipilimumab may cause immune-related pneumonia, and patients need to pay attention to symptoms such as breathing problems and coughing.

3.Immune-related liver function abnormalities: Liver function needs to be monitored during treatment in order to promptly detect and manage liver function abnormalities.

4.Immune-related neurological problems: Patients should pay close attention to symptoms of neurological problems, such as paresthesia or neuritis.

8. Contraindications:

The use of ipilimumab may be limited or contraindicated in the following circumstances:

1.Patients with a known allergy to ipilimumab or any component of the drug.

2.A history of severe autoimmune diseases, such as systemic lupus erythematosus.

9. Drug interactions:

Ipilimumab may interact with other medications, so patients should inform their doctor about all medications, herbs, supplements, and over-the-counter medications they are using before starting treatment. Your doctor will evaluate potential interactions and make adjustments as needed.

10. Medication for special groups:

1.Children: The safety and effectiveness of ipilimumab in children have not been established, so its use in children may be limited

2.Pregnant and lactating women: Ipilimumab may have adverse effects on the fetus, so its use during pregnancy and lactation requires careful consideration.

11. Listing and price situation:

Ipilimumab is not currently available in China, so patients cannot purchase it domestically and can only purchase it through overseas purchase channels. There are only original drugs of Ipilimumab abroad, mainly Turkish original drugs and Bristol-Myers Squibb original drugs. The price of Turkish original drugs is around 12,000 yuan, and the specification is 50mg/10ml; Bristol-Myers Squibb's original drug is priced around 11,700 yuan, and its specifications are also 50mg/10ml. The ingredients of the two drugs are the same.